In the frontline setting, ivosidenib (500 mg daily) in combination with intensive chemotherapy showed clinical efficacy (cCR rate of 80%) in a phase I trial of 60 newly diagnosed AML patients with an IDH1 mutation [43]. This evidence concerns the gene IDH1 and acute myeloid leukemia.